- Details
- Zachary Klaassen discusses the future of bladder cancer treatment with Mark Tyson. They explore the challenges of sequencing treatments for non-muscle invasive bladder cancer, particularly in BCG-naive and unresponsive patients. Dr. Tyson emphasizes the evolving landscape with multiple emerging drugs like Adstiladrin and N-803, which recently received FDA approval. They examine the difficulty in d...
|
- Details
- Zach Klaassen discusses the evolving landscape of non-metastatic castration-resistant prostate cancer (nmCRPC) with Neal Shore. They delve into the significant impact of PSMA PET scans on diagnosing and treating nmCRPC. Dr. Shore reflects on three pivotal trials—SPARTAN, PROSPER, and ARAMIS—that have redefined treatment approaches by demonstrating the efficacy of apalutamide, enzalutamide, and dar...
|
- Details
- Sam Chang engages with Ashish Kamat to discuss integrating Adstiladrin into regular clinical practice. During their conversation, Dr. Kamat elaborates on Adstiladrin's journey from clinical trials to its current commercial use, highlighting its 53% complete response rate. They explore the challenges and decisions involved in choosing treatments for BCG-unresponsive non-muscle invasive bladder canc...
|
- Details
- Sam Chang hosts Rob Svatek who discusses the PIVOT-006 trial. This phase three trial targets intermediate-risk, non-muscle invasive bladder cancer, comparing a novel therapy, Cretostimogene grenadenorepvec (Creto), against observation. The goal is to enroll 364 patients over 30 months to demonstrate a 10% improvement in recurrence-free survival. The trial focuses on patients who do not qualify as...
|
- Details
- Preston Sprenkle and Eric Kim discuss the future of prostate cancer diagnostics, emphasizing the role of genomic classifiers like PAM50 and MRI in refining patient treatment plans. Dr. Kim suggests that prostate cancer care may soon parallel advances in breast cancer, utilizing gene pathway analyses to guide treatment decisions more accurately. They explore how integrating complex biomarkers into...
|
- Details
- Sam Chang speaks with Mark Tyson about the BOND-003 trial's findings on cretostimogene grenadenorepvec for treating BCG unresponsive carcinoma in situ of the bladder. Dr. Tyson explains the dual-action mechanism of the drug, combining direct tumor cell destruction with enhanced immune response activation. Impressively, the trial shows a 75.2% complete response rate at various time points with a ti...
|
- Details
- Preston Sprenkle discusses with Eric Kim the integration of MRI and genomic classifiers in prostate cancer management. They explore the potential of artificial intelligence (AI) to enhance diagnostic accuracy and personalization of treatment. Dr. Kim reflects on his project, which investigates correlations between MRI findings and genomic data from a large cohort, noting the challenges of consiste...
|
- Details
- Eric Kim discusses the variation in prostate cancer genomic subtypes related to MRI PI-RADS scores and racial differences. He focused on the correlations between mpMRI findings and the Decipher genomic classifier in a racially diverse cohort of men. The study revealed that MRI and Decipher scores generally correlated well, especially in non-African Americans, but this correlation was weaker among...
|
- Details
- Alicia Morgans hosts a discussion with Massimo Alfano and Filippo Pederzoli on the promising link between the stool microbiome and the effectiveness of neoadjuvant pembrolizumab in treating muscle-invasive bladder cancer. This intriguing connection explores how the microbiome could serve as a predictive biomarker for immunotherapy outcomes. Dr. Alfano credits the genesis of their research to prior...
|
- Details
- Rana McKay discusses her team’s study on the HSD3B1 gene and its link to prostate cancer outcomes, published in JAMA Network Open. The study focuses on the adrenal-permissive allele of HSD3B1, which influences the body's conversion of DHEA to potent androgens, affecting responses to hormonal therapy and prostate cancer progression. Dr. McKay explains that this genetic variant shows variable preval...
|
